TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 22924949

Group type: EXPERIMENTAL
Intervention: Tofacitinib 2 mg twice daily
Number of subjects: 197

Group type: EXPERIMENTAL
Intervention: Tofacitinib 5 mg twice daily
Number of subjects: 197

Group type: EXPERIMENTAL
Intervention: Tofacitinib 15 mg twice daily
Number of subjects: 197

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 197

Group type: EXPERIMENTAL
Intervention: Tofacitinib (all doses)
Number of subjects: 197
Study: 20668250

Group type: EXPERIMENTAL
Intervention: Barley protein
Number of subjects: 23

Group type: COMPARATOR
Intervention: Calcium caseinate
Number of subjects: 23
Study: 18590518

Group type: EXPERIMENTAL
Intervention: Computerised cognitive behavioural therapy (CBT)
Number of subjects: 300

Group type: COMPARATOR
Intervention: Treatment as usual by a GP
Number of subjects: 300

Group type: EXPERIMENTAL
Intervention: Computerised cognitive behavioural therapy in combination with usual GP care
Number of subjects: 300
Study: 16092109

Group type: EXPERIMENTAL
Intervention: Long-term antiparkinson therapy
Number of subjects: 21

Group type: COMPARATOR
Intervention: Healthy controls
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: Patients before therapy
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: Correlation with motor improvement
Number of subjects: 21
Study: 12042268

Group type: EXPERIMENTAL
Intervention: Double lumen catheter (CC)
Number of subjects: 650

Group type: COMPARATOR
Intervention: Single lumen catheter (TCC)
Number of subjects: 650
Study: 10598602

Group type: EXPERIMENTAL
Intervention: Electrical stimulation for 30 min
Number of subjects: 75

Group type: EXPERIMENTAL
Intervention: Electrical stimulation for 45 min
Number of subjects: 75

Group type: EXPERIMENTAL
Intervention: Electrical stimulation for 15 min
Number of subjects: 75

Group type: COMPARATOR
Intervention: Electrical stimulation for 0 min (sham treatment)
Number of subjects: 75

Group type: EXPERIMENTAL
Intervention: Electrical stimulation for 30 min and 45 min
Number of subjects: 75

Group type: EXPERIMENTAL
Intervention: Electrical stimulation for 15 to 45 min
Number of subjects: 75
Study: 7489529

Group type: EXPERIMENTAL
Intervention: Walking program (54.3 ± 7.7 mins/day, 4.9 ± 1.7 days/week, 54% maximum heart rate reserve, for six months)
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: Walking program
Number of subjects: 25

Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 25
Study: 1538102

Group type: EXPERIMENTAL
Intervention: Self-selected wrist position (35 degrees of extension and 7 degrees of ulnar deviation)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Wrist deviated into flexion, extension, or radial/ulnar deviation of 10 to 15 degrees
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Self-selected position with a minimum of 25 degrees of wrist extension
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Grasp size using Jamar dynamometer
Number of subjects: 20
Study: 6087753

Group type: EXPERIMENTAL
Intervention: Sulfamethoxazole and trimethoprim
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Ketoconazole
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Combination of sulfamethoxazole and trimethoprim and ketoconazole
Number of subjects: 0

Group type: COMPARATOR
Intervention: No prophylaxis
Number of subjects: 0
Study: 31195244

Group type: EXPERIMENTAL
Intervention: Varenicline
Number of subjects: 285

Group type: EXPERIMENTAL
Intervention: Bupropion
Number of subjects: 285

Group type: EXPERIMENTAL
Intervention: Nicotine Replacement Therapy (NRT)
Number of subjects: 285

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 285

Group type: COMPARATOR
Intervention: Overall comparison (BD vs NPC)
Number of subjects: 285
Study: 30449275

Group type: EXPERIMENTAL
Intervention: Fluralaner plus moxidectin (Bravecto® Plus) - minimum dose rates 40 mg/kg and 2 mg/kg, respectively
Number of subjects: 273

Group type: COMPARATOR
Intervention: Emodepside plus praziquantel (Profender®) - minimum dose rates 3 mg/kg and 12 mg/kg, respectively
Number of subjects: 273
Study: 27320173

Group type: EXPERIMENTAL
Intervention: Simvastatin plus extended release niacin (ERN), 1500 to 2000 mg/day
Number of subjects: 3094

Group type: COMPARATOR
Intervention: Simvastatin plus placebo
Number of subjects: 3094
Study: 24571700

Group type: EXPERIMENTAL
Intervention: Stannous fluoride (SnF2) dentifrice (1,100 ppm F)
Number of subjects: 3

Group type: EXPERIMENTAL
Intervention: Sodium fluoride (NaF) dentifrice (1,100 ppm F)
Number of subjects: 3

Group type: EXPERIMENTAL
Intervention: Sodium monofluorophosphate (SMFP) dentifrice (1,000 ppm F)
Number of subjects: 3

Group type: EXPERIMENTAL
Intervention: Amine fluoride (AmF) dentifrice (1,400 ppm F)
Number of subjects: 3
Study: 22898678

Group type: EXPERIMENTAL
Intervention: Vandetanib 300 mg per day
Number of subjects: 145

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 145
Study: 20693876

Group type: EXPERIMENTAL
Intervention: 0.5 mg/kg intravenous ketamine on induction of anesthesia and continuous infusion at 10 microg kg(‐1) min(‐1) until wound closure
Number of subjects: 102

Group type: EXPERIMENTAL
Intervention: 0.5 mg/kg intravenous ketamine
Number of subjects: 102

Group type: COMPARATOR
Intervention: Saline of equivalent volume (placebo)
Number of subjects: 102
Study: 18931624

Group type: EXPERIMENTAL
Intervention: Community-based HIV mobile voluntary counseling and testing
Number of subjects: 48

Group type: COMPARATOR
Intervention: Clinic-based standard voluntary counseling and testing (VCT)
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: Overall adherence to intervention components
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: Study outcomes including prevalence of recent HIV infection and community-level HIV stigma
Number of subjects: 48
Study: 16401958

Group type: EXPERIMENTAL
Intervention: Enalapril
Number of subjects: 51

Group type: COMPARATOR
Intervention: Control
Number of subjects: 51
Study: 12876177

Group type: EXPERIMENTAL
Intervention: Human synthetic secretin (HSS) 2 CU/kg
Number of subjects: 62

Group type: COMPARATOR
Intervention: Placebo (saline)
Number of subjects: 62
Study: 10561942

Group type: EXPERIMENTAL
Intervention: 0.05 per cent isotretinoin gel (Isotrex)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Vehicle base with broad spectrum sunscreen (SPF 28)
Number of subjects: 30
Study: 8712430

Group type: EXPERIMENTAL
Intervention: Before group (22 patients, 11 failed blocks)
Number of subjects: 46

Group type: EXPERIMENTAL
Intervention: After group (12 patients)
Number of subjects: 46

Group type: COMPARATOR
Intervention: None group (12 patients)
Number of subjects: 46
Study: 2070703

Group type: EXPERIMENTAL
Intervention: Amantadine (100 mg nocte)
Number of subjects: 124

Group type: EXPERIMENTAL
Intervention: Bromocriptine (2.5 mg twice daily)
Number of subjects: 124

Group type: COMPARATOR
Intervention: Cimetidine (800 mg nocte)
Number of subjects: 124

Group type: COMPARATOR
Intervention: Famotidine (40 mg nocte)
Number of subjects: 124
Study: 6680214

Group type: EXPERIMENTAL
Intervention: Topical sodium fluoride gel
Number of subjects: 220

Group type: COMPARATOR
Intervention: High content fluoride toothpaste (1350 ppm F‐)
Number of subjects: 220
Study: 30936138

Group type: EXPERIMENTAL
Intervention: Nurses' identification of low cardiac output syndrome based on survey responses at 5 time points (0, 6, 12, 18, and 24 hours postoperatively).
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Analysis of agreement by years of experience of nurses.
Number of subjects: 10
Study: 28454522

Group type: EXPERIMENTAL
Intervention: Behavioral activation training
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Mindfulness-based training
Number of subjects: 60

Group type: COMPARATOR
Intervention: Control group (depression only)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Control group (alcohol use disorder only)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Healthy control group
Number of subjects: 60
Study: 25548261

Group type: EXPERIMENTAL
Intervention: High-fat diet (CETP rs3764261 CC genotype)
Number of subjects: 903

Group type: COMPARATOR
Intervention: Low-fat diet (CETP rs3764261 CC genotype)
Number of subjects: 903

Group type: EXPERIMENTAL
Intervention: High-fat diet (other genotypes)
Number of subjects: 903

Group type: COMPARATOR
Intervention: Low-fat diet (other genotypes)
Number of subjects: 903

Group type: EXPERIMENTAL
Intervention: Low-carbohydrate/high-fat weight-loss diet (CETP rs3764261 CC genotype)
Number of subjects: 903
Study: 24388320

Group type: EXPERIMENTAL
Intervention: Inhaled nitric oxide therapy
Number of subjects: 512

Group type: COMPARATOR
Intervention: ICU readmission
Number of subjects: 512

Group type: COMPARATOR
Intervention: Health care costs
Number of subjects: 512
Study: 22414819

Group type: EXPERIMENTAL
Intervention: Zinc supplementation (10 mg/d)
Number of subjects: 826

Group type: EXPERIMENTAL
Intervention: Zinc supplementation (10 mg/d) after vitamin A supplementation (200,000 IU)
Number of subjects: 826

Group type: EXPERIMENTAL
Intervention: Vitamin A supplementation (200,000 IU)
Number of subjects: 826

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 826
Study: 20014458

Group type: COMPARATOR
Intervention: PEG‐IFN plus ribavirin (PR)
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: PEG‐IFN plus ketoprofen
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: PEG‐IFN plus ribavirin and ketoprofen
Number of subjects: 45
Study: 17595779

Group type: EXPERIMENTAL
Intervention: 7 or more courses of intravenous topotecan
Number of subjects: 523

Group type: COMPARATOR
Intervention: 6 or fewer courses of intravenous topotecan
Number of subjects: 523

Group type: EXPERIMENTAL
Intervention: topotecan treatment
Number of subjects: 523
Study: 15250785

Group type: EXPERIMENTAL
Intervention: Context noise and item noise
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Experimental data fitting with retrieving effectively from memory model
Number of subjects: 0
Study: 11991908

Group type: EXPERIMENTAL
Intervention: Standard surgery (transurethral resection of the prostate)
Number of subjects: 340

Group type: COMPARATOR
Intervention: Laser therapy (non-contact laser therapy)
Number of subjects: 340

Group type: COMPARATOR
Intervention: Conservative management (no active intervention)
Number of subjects: 340
Study: 9865685

Group type: EXPERIMENTAL
Intervention: Docetaxel (Taxotere)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Mitomycin C and vinblastine
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Docetaxel
Number of subjects: 0

Group type: COMPARATOR
Intervention: Doxorubicin
Number of subjects: 0
Study: 7630998

Group type: EXPERIMENTAL
Intervention: Dance for Health intervention (aerobic dance program, health education curriculum twice a week, dance-oriented physical education class three times a week)
Number of subjects: 110

Group type: COMPARATOR
Intervention: Usual physical activity (mostly playground activities)
Number of subjects: 110
Study: 7455835

Group type: EXPERIMENTAL
Intervention: Iron deficiency (including iron deficiency anaemia)
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Iron deficiency anaemia
Number of subjects: 15

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 15
Study: 30690869

Group type: EXPERIMENTAL
Intervention: Ready-to-Use Supplementary Food (RUSF) as a snack
Number of subjects: 95

Group type: EXPERIMENTAL
Intervention: Ready-to-Use Supplementary Food (RUSF) mixed with borbor (white rice porridge)
Number of subjects: 95

Group type: COMPARATOR
Intervention: Corn-soy blend plus plus (CSB++)
Number of subjects: 95

Group type: COMPARATOR
Intervention: Borbor fortified with micronutrient powder (MNP)
Number of subjects: 95

Group type: EXPERIMENTAL
Intervention: Ready-to-Use Supplementary Food (RUSF) snack
Number of subjects: 95
Study: 28141620

Group type: EXPERIMENTAL
Intervention: Cold-water immersion (CWI) at 8°C for 10 min
Number of subjects: 10

Group type: COMPARATOR
Intervention: Whole body cryotherapy (WBC) at -110°C for 2 min
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Both CWI and WBC
Number of subjects: 10
Study: 26107810

Group type: EXPERIMENTAL
Intervention: Glucose
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Fructose
Number of subjects: 12

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study: 24401143

Group type: EXPERIMENTAL
Intervention: Robot-assisted gait training (RAGT) for 16 sessions (45 min each)
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: Strength training for 16 sessions (45 min each)
Number of subjects: 9

Group type: COMPARATOR
Intervention: Both interventions (RAGT and strength training)
Number of subjects: 9
Study: 22452620

Group type: EXPERIMENTAL
Intervention: Enteral nutrition (35 kcal/Kg/day for 4 weeks followed by oral nutritional support for 2 months)
Number of subjects: 99

Group type: COMPARATOR
Intervention: Symptomatic support (control group)
Number of subjects: 99

Group type: EXPERIMENTAL
Intervention: Enteral nutrition
Number of subjects: 99
Study: 19167189

Group type: EXPERIMENTAL
Intervention: Combined transbuccal and intra-oral approach
Number of subjects: 140

Group type: COMPARATOR
Intervention: Intra-oral alone
Number of subjects: 140
Study: 17678493

Group type: EXPERIMENTAL
Intervention: Stimulant medications
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Atomoxetine
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Selective serotonin reuptake inhibitors (SSRIs)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Intensive behavior modification
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Cognitive-behavioral therapy (CBT)
Number of subjects: 0
Study: 15364688

Group type: EXPERIMENTAL
Intervention: 1.25 U of botulinum toxin type A
Number of subjects: 13

Group type: EXPERIMENTAL
Intervention: 2.5 U of botulinum toxin type A
Number of subjects: 13

Group type: EXPERIMENTAL
Intervention: 3.75 U of botulinum toxin type A
Number of subjects: 13

Group type: EXPERIMENTAL
Intervention: All doses of botulinum toxin type A
Number of subjects: 13
Study: 12324288

Group type: EXPERIMENTAL
Intervention: Dietary counseling with an extra 350 micro g folate derived from food/d
Number of subjects: 0

Group type: COMPARATOR
Intervention: Unfortified breakfast cereal (control group)
Number of subjects: 0
Study: 11475744

Group type: EXPERIMENTAL
Intervention: Chanlibao (CLB)
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Oxytocin (OTC)
Number of subjects: 80

Group type: COMPARATOR
Intervention: Control group (natural labor)
Number of subjects: 80
Study: 7857345

Group type: EXPERIMENTAL
Intervention: Pidotimod 800 mg sachets after fasting
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Pidotimod 800 mg sachets after a standard meal
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Pidotimod 800 mg ampoules after fasting
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Pidotimod 800 mg ampoules after a standard meal
Number of subjects: 12

Group type: COMPARATOR
Intervention: Comparison of both formulations (sachets and ampoules)
Number of subjects: 12
Study: 2632449

Group type: EXPERIMENTAL
Intervention: Systemic aspirin
Number of subjects: 0

Group type: COMPARATOR
Intervention: Systemic vitamin E
Number of subjects: 0
Study: 662249

Group type: EXPERIMENTAL
Intervention: Prostaglandin alone
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Urea alone
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Combination of urea and prostaglandin
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Oxytocin and laminaria used in all groups
Number of subjects: 0
Study: 31390035

Group type: EXPERIMENTAL
Intervention: Healthy Outcomes Through Patient Empowerment (HOPE) - 9 telephone sessions with trained health care professionals using collaborative goal-setting and behavioral activation methods.
Number of subjects: 225

Group type: COMPARATOR
Intervention: Enhanced Usual Care (EUC) - notification of high-risk status.
Number of subjects: 225

Group type: EXPERIMENTAL
Intervention: Healthy Outcomes Through Patient Empowerment (HOPE) - 12 months follow-up.
Number of subjects: 225
Study: 28152177

Group type: EXPERIMENTAL
Intervention: Acupressure on specific acupoints (Tian-Zhu, Ju-Que, Yong-Quan, Bai-Hui, and Nei-Guan) three times a week for 8 weeks, 24 minutes each time
Number of subjects: 62

Group type: COMPARATOR
Intervention: Massage at locations with no acupoints (10 mm from true points) three times a week for 8 weeks, 24 minutes each time
Number of subjects: 62
Study: 26571987

Group type: EXPERIMENTAL
Intervention: Ethanolic leaf extracts of Ocimum sanctum (EtOS) 300 mg per day for 30 days
Number of subjects: 100

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Ethanolic leaf extracts of Ocimum sanctum (EtOS)
Number of subjects: 100
Study: 24083543

Group type: EXPERIMENTAL
Intervention: 12 week exercise and counseling program (3 hours + 30 minutes per week of supervised and structured aerobic training at moderate to high intensity 70‐80%, strength exercises using hand weights, relaxation exercise, individual health counseling sessions with a self-directed home walk program)
Number of subjects: 70

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 70
Study: 22145768

Group type: EXPERIMENTAL
Intervention: Internet-based treatment group
Number of subjects: 53

Group type: COMPARATOR
Intervention: Face-to-face group
Number of subjects: 53

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 53
Study: 19487510

Group type: EXPERIMENTAL
Intervention: Patellar eversion and anterior tibial translation
Number of subjects: 37

Group type: COMPARATOR
Intervention: Patellar subluxation and no tibial translation
Number of subjects: 37
Study: 17292768

Group type: EXPERIMENTAL
Intervention: Azithromycin
Number of subjects: 224

Group type: EXPERIMENTAL
Intervention: Clarithromycin
Number of subjects: 224

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 224

Group type: EXPERIMENTAL
Intervention: Azithromycin vs Clarithromycin
Number of subjects: 224
Study: 15750254

Group type: EXPERIMENTAL
Intervention: Essential hypertension patients
Number of subjects: 115

Group type: COMPARATOR
Intervention: Normal controls
Number of subjects: 115
Study: 11281559

Group type: EXPERIMENTAL
Intervention: 100 IU/day of salmon calcitonin subcutaneously for the first 6 months posttransplant
Number of subjects: 63

Group type: COMPARATOR
Intervention: No therapy
Number of subjects: 63

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 63
Study: 9153604

Group type: EXPERIMENTAL
Intervention: Early follow up group (additional information, advice, support, and further intervention offered at 7-10 days after injury)
Number of subjects: 1156

Group type: COMPARATOR
Intervention: Standard service (control group)
Number of subjects: 1156
Study: 7505423

Group type: EXPERIMENTAL
Intervention: Aspartame (34 mg/kg single morning dose)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 3112002

Group type: EXPERIMENTAL
Intervention: MCT/LCT fat emulsion
Number of subjects: 20

Group type: COMPARATOR
Intervention: LCT fat emulsion
Number of subjects: 20
Study: 29218549

Group type: EXPERIMENTAL
Intervention: FreeStyle Navigator I
Number of subjects: 155
Study: 27056638

Group type: EXPERIMENTAL
Intervention: Ipragliflozin 25-50 mg/day
Number of subjects: 63

Group type: COMPARATOR
Intervention: Alogliptin 12.5-25 mg/day
Number of subjects: 63
Study: 24726046

Group type: EXPERIMENTAL
Intervention: Adverse Childhood Experiences (ACE) scale
Number of subjects: 364
Study: 23849502

Group type: EXPERIMENTAL
Intervention: 30-minute face-to-face educational intervention covering pain assessment and management, augmented by a leaflet and follow-up telephone call at two weeks
Number of subjects: 0

Group type: COMPARATOR
Intervention: Usual care (wait-list control group)
Number of subjects: 0
Study: 20479759

Group type: EXPERIMENTAL
Intervention: Weekly high-dose EPO for 3 months
Number of subjects: 32

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 32
Study: 18349391

Group type: EXPERIMENTAL
Intervention: Chemo-endocrine therapy (CMF chemotherapy for 6 cycles followed by goserelin)
Number of subjects: 2732

Group type: COMPARATOR
Intervention: Endocrine therapy alone (goserelin or tamoxifen)
Number of subjects: 2732

Group type: COMPARATOR
Intervention: Tamoxifen alone
Number of subjects: 2732

Group type: EXPERIMENTAL
Intervention: Chemo-endocrine therapy (CMF followed by tamoxifen for 5 years)
Number of subjects: 2732
Study: 16735589

Group type: EXPERIMENTAL
Intervention: Arthroscopic stabilization
Number of subjects: 64

Group type: COMPARATOR
Intervention: Open stabilization
Number of subjects: 64
Study: 14646613

Group type: EXPERIMENTAL
Intervention: etilevodopa/carbidopa swallowed tablets
Number of subjects: 29

Group type: EXPERIMENTAL
Intervention: etilevodopa/carbidopa tablets dissolved in water
Number of subjects: 29

Group type: EXPERIMENTAL
Intervention: etilevodopa oral solution with carbidopa tablets
Number of subjects: 29

Group type: COMPARATOR
Intervention: standard levodopa/carbidopa tablets
Number of subjects: 29
Study: 10961868

Group type: EXPERIMENTAL
Intervention: Weekly PEG‐Asp dosing
Number of subjects: 144
Study: 9005361

Group type: EXPERIMENTAL
Intervention: 10 mg of folic acid daily for 6 months
Number of subjects: 154

Group type: COMPARATOR
Intervention: Placebo daily for 6 months
Number of subjects: 154
Study: 1289091

Group type: EXPERIMENTAL
Intervention: Supplementation of normal diet with 3 g of omega-3 polyunsaturated fatty acids per day for 6 months (treatment group)
Number of subjects: 120

Group type: COMPARATOR
Intervention: Standard therapy only (control group)
Number of subjects: 120
Study: 2865857

Group type: EXPERIMENTAL
Intervention: Celiprolol (300 mg per day)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Propranolol (160 mg per day)
Number of subjects: 20
Study: 30861097

Group type: EXPERIMENTAL
Intervention: In-person counseling
Number of subjects: 278

Group type: EXPERIMENTAL
Intervention: Telephone counseling
Number of subjects: 278

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 278

Group type: EXPERIMENTAL
Intervention: All groups (including controls)
Number of subjects: 278

Group type: EXPERIMENTAL
Intervention: In-person and telephone interventions
Number of subjects: 278
Study: 29353523

Group type: EXPERIMENTAL
Intervention: Hook plate stabilization
Number of subjects: 76

Group type: COMPARATOR
Intervention: Arthroscopically assisted tight rope stabilization
Number of subjects: 76
Study: 27100799

Group type: EXPERIMENTAL
Intervention: Cognitive Behavioral Group Therapy (CBGT) for 12 weeks
Number of subjects: 150

Group type: COMPARATOR
Intervention: Waiting List (WL)
Number of subjects: 150

Group type: EXPERIMENTAL
Intervention: Cognitive Behavioral Group Therapy (CBGT)
Number of subjects: 150
Study: 25310750

Group type: EXPERIMENTAL
Intervention: 1,550-nm fractional erbium glass laser (30-40 mJ)
Number of subjects: 24
Study: 22844979

Group type: EXPERIMENTAL
Intervention: 25 mg ketamine lozenge
Number of subjects: 22

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 22